Amenamevir Market

The Amenamevir market is witnessing a CAGR of 2.5% during the forecast period of 2025-2035. Amenamevir is an antiviral drug categorized as a helicase-primase inhibitor, primarily utilized for the treatment of herpes zoster (shingles) and recurrent herpes simplex infections. Unlike traditional antiviral medications such as acyclovir, amenamevir targets the helicase-primase complex, disrupting viral DNA replication and offering an alternative mechanism of action. The drug was first approved in Japan under the brand name Amenalief® by Maruho Co., Ltd. in 2017 for treating herpes zoster, with its indications later expanding in 2023 to include recurrent herpes simplex infections. To broaden its market presence, Maruho entered a licensing agreement with Hyphens Pharma International Limited in June 2024, allowing for the development and commercialization of amenamevir across ten ASEAN countries. Additionally, Syn-Tech Chem. & Pharm. Co., Ltd., a Taiwan-based company, has been identified as a key manufacturer involved in the production and API supply of the drug. Reports on procurement and production costs have provided insights into manufacturing efficiency and supply chain optimization.

Clinical studies have reinforced the drug’s efficacy and safety, with over 1.24 million patients in Japan having been treated for herpes zoster. Research has also demonstrated the effectiveness of single-dose, patient-initiated therapy for recurrent genital herpes, positioning amenamevir as a convenient and effective alternative to conventional treatments. As research continues and its market reach expands, amenamevir is expected to play an increasingly significant role in the global antiviral therapy landscape.